Names and pronunciation
(a-ten′oh-lole) Tenormin, Tenorectic
Source page 116
Loading InternPractice…
Individual generic drug information
Extracted information for atenolol only.
(a-ten′oh-lole) Tenormin, Tenorectic
Source page 116
Func. class.: Antihypertensive, antianginal
Source page 116
Chem. class.: β-Blocker, β1-, β2- blocker (high doses)
Source page 116
Do not confuse: atenolol/albuterol Tenormin/thiamine/Imuran
Source page 116
ACTION: Competitively blocks stimu- lation of β-adrenergic receptor within vascular smooth muscle; produces nega- tive chronotropic activity (decreases rate of SA node discharge, increases recovery time), slows conduction of AV node, decreases heart rate, negative inotropic activity decreases O2 consumption in myocardium; decreases action of renin- aldosterone-angiotensin system at high doses, inhibits β2 receptors in bronchial system at higher doses
Source page 116
USES: Hypertension, angina pectoris; suspected or known MI (IV use); MI prophylaxis
Source page 116
Unlabeled uses: Migraine prophylaxis, supraventricular tachycardia prophylaxis (PSVT), unstable angina, alcohol with- drawal, lithium-induced tremor
Source page 116
Extracted information for atenolol only.
CONTRAINDICATIONS: Preg- nancy, hypersensitivity to β-blockers, car- diogenic shock, second- or third-degree heart block, sinus bradycardia, cardiac failure Precautions: Breastfeeding, major surgery, diabetes mellitus, thyroid/ renal disease, HF, COPD, asthma, well- compensated heart failure, dialysis, myasthenia gravis, Raynaud’s disease, pulmonary edema
Source pages 116, 117
Black Box Warning: Abrupt discontinu- ation Black Box Warning: Taper gradually, do not discontinue abruptly, may precipitate angina, MI • If pregnancy is planned or suspected; do not use in pregnancy, breastfeeding Black Box Warning: Not to discontinue product abruptly, taper over 2 wk (an- gina); to take at same time each day as directed • Not to use OTC products unless di- rected by prescriber • To report bradycardia, dizziness, con- fusion, depression, fever • To take pulse at home; advise when to notify prescriber (heart rate <50 bpm) • To limit alcohol, smoking, sodium intake • To comply with weight control, dietary adjustments, modified exercise program • To carry emergency ID to identify prod- uct, allergies, conditions being treated • To avoid hazardous activities if dizzi- ness is present • To change position slowly to limit or- thostatic hypotension • That product may mask symptoms of hypoglycemia in diabetic patients • Pregnancy/breastfeeding: if preg- nancy is planned or suspected; do not use in pregnancy, breastfeeding; to use con- traception while taking this product; to avoid breastfeeding
Source pages 117, 118
SIDE EFFECTS CNS: Insomnia, fatigue, dizziness, mental changes, memory loss, depres- sion, lethargy, drowsiness, strange dreams CV: Profound hypotension, bradycardia, HF ENDO: Hypo- and hyperglycemia GI: Nausea, diarrhea, vomiting, constipation GU: Impotence, decreased libido, uri- nary frequency INTEG: Rash RESP: Bronchospasm, dyspnea, wheez- ing, pulmonary edema
Source page 117
INTERACTIONS • Mutual inhibition: sympathomimetics (cough, cold preparations) Increase: hypotension, bradycardia— reserpine, hydrALAZINE, methyldopa, pra- zosin, anticholinergics, digoxin, diltiaZEM, verapamil, cardiac glycosides, calcium channel blockers, antihypertensives; mon- itor and adjust dose if needed Increase: hypoglycemia—insulins, oral antidiabetics Increase: hypertension—amphetamines, ePHEDrine, pseudoephedrine Increase: toxicity risk—dolasetron; lido- caine (IV) Decrease: atenolol effect—salicylates, rifamycins, penicillins, NSAIDs, calcium carbonate, aluminum antacids Drug/Herb Increase: atenolol effect—hawthorn Decrease: atenolol effect—ephedra (ma huang) Drug/Lab Test Increase: BUN, potassium, triglycerides, uric acid, ANA titer, platelets, alkaline phosphatase, creatinine, LDH, AST/ALT Decrease: glucose
Source page 117
TREATMENT OF OVERDOSE: Lavage, IV atropine for bradycardia, IV theophylline for bronchospasm, dextrose for hypoglycemia, digoxin, O2, diuretic for cardiac failure, hemodialysis HIGH ALERT
Source page 118
Extracted information for atenolol only.
DOSAGE AND ROUTES Hypertension • Adult: PO 25-50 mg/day, increasing q1-2wk to 100 mg/day; may increase to 200 mg/day for angina, up to 100 mg/ day for hypertension • Child: PO 0.8-1 mg/kg/dose initially; range, 0.8-1.5 mg/kg/day; max 2 mg/kg/ day; max 2mg/kg/day up to 100mg/day • Geriatric: PO 25 mg/day initially MI • Adult: PO 100 mg/day in 1-2 divided doses; may need for 1-3 yr after MI Renal disease • Adult: PO CCr 15-35 mL/min, max 50 mg/day; CCr <15 mL/min, max 25 mg/ day; hemodialysis 25-50 mg after dialy- sis PSVT prophylaxis (unlabeled) • Child: PO 0.3-1.3 mg/kg/day Cardiac risk reduction during sur- gery (unlabeled) • Adult: PO 50 mg, start before planned procedure, titrate to heart rate, continue 7-30 days after procedure Unstable angina (unlabeled) • Adult: PO 50-200 mg/day Ethanol withdrawal prevention (unlabeled) • Adult: PO 50-100 mg/day Migraine prophylaxis (unlabeled) • Adult: PO 50-150 mg/day, titrate to response Lithium-induced tremor (unlabeled) • Adult: PO 50 mg/day
Source page 117
Available forms: Tablets 25, 50, 100 mg
Source page 117
Administer: PO route • Before meals, at bedtime; tablet may be crushed, swallowed whole, same time of day • Reduced dosage with renal dysfunction A • Store protected from light, moisture; place in cool environment
Source page 117
Extracted information for atenolol only.
Assess: • I&O, weight daily; watch for HF (rales/ crackles, jugular vein distention, weight gain, edema) • Hypertension: B/P, pulse q4hr; note rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of any significant changes (<50 bpm); ECG • Hypoglycemia: may be masked in dia- betes mellitus (tachycardia, sweating)
Source page 118
Evaluate: • Therapeutic response: decreased B/P after 1-2 wk, increased activity tolerance, decreased anginal pain
Source page 118
CLINICAL CONSIDERATIONS
Source page 118
Patient and caregiver information:
Source page 118
Extracted information for atenolol only.
PHARMACOKINETICS PO: Peak 2-4 hr; onset 1 hr; duration 24 hr; half-life 6-7 hr; excreted unchanged in urine, feces (50%); protein binding 5%-15%
Source page 117
Filter the extracted dose blocks for this individual drug.
Hypertension
• Child: PO 0.8-1 mg/kg/dose initially; range, 0.8-1.5 mg/kg/day; max 2 mg/kg/ day; max 2mg/kg/day up to 100mg/day
Candidate age grouping · source page 117
Hypertension
• Child: PO 0.3-1.3 mg/kg/day Cardiac risk reduction during sur- gery (unlabeled)
Candidate age grouping · source page 117